Steven D. Rubin
Net Worth
Last updated:
What is Steven D. Rubin net worth?
The estimated net worth of Mr. Steven D. Rubin is at least $20,529,385 as of 5 Jan 2024. He owns shares worth $8,353,438 as insider, has earned $1,500,347 from insider trading and has received compensation worth at least $10,675,600 in OPKO Health, Inc..
What is the salary of Steven D. Rubin?
Mr. Steven D. Rubin salary is $821,200 per year as Executive Vice President of Admin. & Director in OPKO Health, Inc..
How old is Steven D. Rubin?
Mr. Steven D. Rubin is 65 years old, born in 1960.
What stocks does Steven D. Rubin currently own?
As insider, Mr. Steven D. Rubin owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| OPKO Health, Inc. (OPK) | Executive Vice President of Admin. & Director | 6,187,732 | $1.35 | $8,353,438 |
What does OPKO Health, Inc. do?
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Steven D. Rubin insider trading
OPKO Health, Inc.
Mr. Steven D. Rubin has made 2 insider trades between 2012-2024, according to the Form 4 filled with the SEC. Most recently he purchased 10,000 units of OPK stock worth $8,670 on 5 Jan 2024.
The largest trade he's ever made was exercising 5,832,598 units of OPK stock on 31 Jan 2015. As of 5 Jan 2024 he still owns at least 6,187,732 units of OPK stock.